Daily Respiratory Research Analysis
A phase 3 trial showed that adding platinum–pemetrexed chemotherapy to first-line osimertinib improved overall survival in EGFR-mutated lung cancer, albeit with more grade ≥3 adverse events. Real-world data confirmed high effectiveness of nirsevimab against RSV infection and severe outcomes in infants. Mechanistic work identified SLC26A9 as essential for neonatal airway chloride secretion and mucociliary clearance, linking ion transport to early-life respiratory failure.
Summary
A phase 3 trial showed that adding platinum–pemetrexed chemotherapy to first-line osimertinib improved overall survival in EGFR-mutated lung cancer, albeit with more grade ≥3 adverse events. Real-world data confirmed high effectiveness of nirsevimab against RSV infection and severe outcomes in infants. Mechanistic work identified SLC26A9 as essential for neonatal airway chloride secretion and mucociliary clearance, linking ion transport to early-life respiratory failure.
Research Themes
- Optimization of targeted therapy in EGFR-mutated NSCLC
- Real-world effectiveness of RSV immunoprophylaxis in infants
- Ion transport mechanisms driving neonatal respiratory disease
Selected Articles
1. Survival with Osimertinib plus Chemotherapy in
In a phase 3, international, open-label trial (n=557), adding platinum–pemetrexed chemotherapy to first-line osimertinib improved median overall survival from 37.6 to 47.5 months (HR 0.77; P=0.02) in EGFR-mutated NSCLC. Toxicity increased, with grade ≥3 adverse events in 70% vs 34%.
Impact: This is definitive phase 3 evidence of an overall survival benefit with a new first-line strategy for EGFR-mutated NSCLC, likely to influence treatment guidelines.
Clinical Implications: For appropriate patients, consider osimertinib plus platinum–pemetrexed as a first-line option, balancing a meaningful OS gain against higher toxicity and the need for supportive care.
Key Findings
- Median overall survival improved to 47.5 months with osimertinib plus platinum–pemetrexed versus 37.6 months with osimertinib alone.
- Hazard ratio for death was 0.77 (95% CI 0.61–0.96; P=0.02).
- Grade ≥3 adverse events occurred in 70% with combination versus 34% with monotherapy; discontinuation of osimertinib in 12% vs 7%.
Methodological Strengths
- Randomized, international, phase 3 design with overall survival endpoint
- Adequate sample size (n=557) and clear reporting of safety outcomes
Limitations
- Open-label design could introduce bias in some secondary endpoints
- Higher toxicity burden may limit applicability in frail patients
Future Directions: Assess optimal sequencing and duration, biomarker-driven selection for combination therapy, and comparative effectiveness versus modern chemoimmunotherapy backbones.
BACKGROUND: The primary analysis of this trial showed that first-line treatment with osimertinib plus chemotherapy with a platinum-based agent and pemetrexed led to significantly longer progression-free survival than osimertinib monotherapy among patients with epidermal growth factor receptor ( METHODS: In this phase 3, international, open-label trial, we randomly assigned in a 1:1 ratio patients with RESULTS: A total of 557 patients were randomly assigned to the osimertinib plus platinum-pemetrexed group (279 patients) or the osimertinib monotherapy group (278 patients). The median overall survival was 47.5 months in the osimertinib plus platinum-pemetrexed group and 37.6 months in the osimertinib monotherapy group (hazard ratio for death, 0.77; 95% confidence interval, 0.61 to 0.96; P = 0.02). Grade 3 or higher adverse events of any cause were reported in 70% of the patients in the osimertinib plus platinum-pemetrexed group and in 34% of the patients in the osimertinib monotherapy group; adverse events leading to the discontinuation of osimertinib were reported in 12% and 7%, respectively. CONCLUSIONS: Among patients with
2. Lack of SLC26A9-mediated chloride secretion causes mucus plugging and severe respiratory distress in neonatal mice.
Genetic deletion of Slc26a9 in neonatal mice led to lethal respiratory distress due to MUC5B-positive mucus plugging, reduced transepithelial potential difference indicating impaired chloride secretion, and sterile neutrophilic inflammation. SLC26A9-mediated chloride transport is essential for mucociliary clearance and survival after birth.
Impact: This study provides in vivo mechanistic proof that SLC26A9 drives airway chloride secretion and mucociliary clearance at birth, highlighting a potential therapeutic modifier/target in cystic fibrosis and muco-obstructive lung diseases.
Clinical Implications: Therapeutic strategies that augment SLC26A9 function or chloride secretion could improve mucociliary clearance in CF and neonatal muco-obstructive conditions; SLC26A9 status may inform precision therapy alongside CFTR modulators.
Key Findings
- Slc26a9-/- neonatal mice exhibited severe respiratory distress with high mortality and MUC5B-positive mucus plugs causing airway obstruction.
- Tracheal explants showed reduced transepithelial potential difference, consistent with decreased chloride secretion.
- Neonatal Slc26a9-/- mice developed hypoxic epithelial degeneration with sterile neutrophilic airway inflammation.
Methodological Strengths
- Multimodal phenotyping (histology, immunohistochemistry, μCT, bioelectric measurements)
- Clear causality via genetic deletion in vivo
Limitations
- Mouse neonatal model—translation to human neonates requires validation
- Mechanisms of SLC26A9 interaction with other ion channels (e.g., CFTR) not directly dissected
Future Directions: Evaluate pharmacologic activation or gene therapy approaches targeting SLC26A9; interrogate interactions with CFTR modulators and assess human neonatal/infant tissues or organoids.
Solute carrier family 26, member 9 (SLC26A9) is an epithelial chloride channel that was identified as a genetic modifier of disease severity of cystic fibrosis (CF) and other chronic muco-obstructive lung diseases. However, data on the in vivo role of SLC26A9 function in lung health and disease remain limited. Here, we investigated the effect of genetic deletion of Slc26a9 (Slc26a9-/-) on the pulmonary phenotype of neonatal mice. We found that lack of Slc26a9 causes severe neonatal respiratory distress with high mortality. Histology, immunohistochemistry, and micro-computed tomography imaging studies identified airway obstruction with MUC5B-positive mucus plugs in neonatal Slc26a9-/- mice. Bioelectric measurements demonstrated a reduced transepithelial potential difference indicative of reduced chloride secretion across tracheal explants of neonatal Slc26a9-/- compared with WT mice. In addition, neonatal Slc26a9-/- mice displayed hypoxic degeneration of airway epithelial cells associated with sterile neutrophilic airway inflammation. Collectively, our data show that SLC26A9-mediated chloride secretion is critical for proper mucociliary clearance, respiratory function, and survival after birth, and identify a role for SLC26A9 in neonatal adaptation during the transition from fetal to neonatal life.
3. Effectiveness of Nirsevimab in Preventing Respiratory Syncytial Virus-related Burden: A Test-negative Case-control Study in Infants With Bronchiolitis in Lombardy Region, Italy.
In a test-negative case-control analysis of 208 infants with bronchiolitis presenting to an ED in Lombardy, nirsevimab effectiveness was 82% against RSV infection, 78% against RSV-related hospitalization, and 84% against ICU admission. Findings support programmatic use during RSV season.
Impact: Provides real-world effectiveness across clinically meaningful outcomes, reinforcing policy decisions to deploy nirsevimab broadly in infant populations.
Clinical Implications: Prioritize timely administration of nirsevimab to eligible infants before RSV season to reduce ED burden, hospitalizations, and ICU admissions.
Key Findings
- Effectiveness against laboratory-confirmed RSV infection: 82%.
- Effectiveness against RSV-related hospitalization: 78%.
- Effectiveness against ICU admission: 84%.
Methodological Strengths
- Test-negative case-control design reduces healthcare-seeking and testing bias
- Evaluation of multiple clinically relevant endpoints (infection, hospitalization, ICU)
Limitations
- Single-region study with modest sample size (n=208) may limit generalizability
- Potential residual confounding inherent to observational designs
Future Directions: Expand multicenter evaluations, assess duration of protection across seasons, and evaluate impact in subgroups (e.g., preterm, comorbidities) and program logistics.
The effectiveness of nirsevimab in preventing the burden of respiratory syncytial virus (RSV)-bronchiolitis was evaluated with a test-negative case-control study in 208 infants presenting to Emergency Department. The effectiveness was 82% against RSV infection, 78% against RSV-related hospitalization, and 84% against intensive care admission. These real-world data support its inclusion in Italian immunization programs.